HYDERABAD, India, August 7, 2017 /PRNewswire/ --
CPhI Conferences, a division of UBM India, which hosts a number of successful pharmaceutical conferences in the country has announced the 2nd Annual Biosimilars Congress India 2017, slated for 8th - 9th August in Hyderabad.
(Logo: http://mma.prnewswire.com/media/542609/UBM_CPhI_Biosimilars_Congress_India_2017_Logo.jpg )
(Logo: http://mma.prnewswire.com/media/471349/UBM_Logo.jpg )
The Indian biosimilar industry is poised for exponential growth owing to the increasing acceptance, entry of new players, and successful launch of biosimilar products. The Indian biosimilar manufacturers are striving to tap this growing opportunity through heavy investments and acquisitions. While biosimilars offer great opportunities to the Indian pharma and biopharma industry, manufacturers also face some unique R&D challenges. With the introduction of a new regulatory policy in India and increased affordability that biosimilars offer, the Indian pharmaceutical companies have started to look at biosimilars as a lucrative sector. The domestic market is expected to grow at an accelerated pace by aiming to reach a target of $40 billion by 2030 and commanding around 20% share of the global market.
CPhI's 2nd Annual Biosimilars Congress India 2017 will discuss various aspects around regulations of biosimilars, R&D, clinical research, program management and commercialisation for biosimilars. Driven by compelling content and speakers, the congress promises to be a platform for industry experts and decision makers to discuss on pertinent trends in biosimilars, deliberate on key concerns the industry faces today and offer innovative solutions that will continue to place India on the roadmap to success in biosimilars. The congress will also have practical case study insights from Indian and international experts along with panel discussions with a Q&A session.
Speaking on the upcoming 2nd Annual Biosimilars Congress India, Mr. Yogesh Mudras, Managing Director, UBM India said, "Biosimilar pathways are still evolving across the world and the major issues pharma companies face are with respect to demonstrating biosimilarity to the reference product. The changing outlook for Biosimilars comes at a time when the global pharmaceutical industry is feeling the combined impact of two key events - a period of patent expirations on many large pharma brands, and an economic situation that has required healthcare systems to make significant and sustained cost reductions. CPhI's 2nd Annual Biosimilars Congress thus comes at the right time, and aims to bring forth the challenges and opportunities to industry professionals, so that they can devise smart strategies to augment the growth of biosimilars."
The conference will also see participation from eminent speakers such as Mr. Cecil Nick, Vice President (Technical), Integrated Product Development, PAREXEL; Dr. Bhaswat S. Chakraborty, Senior Vice President, Research & Development, Cadila Pharmaceuticals Ltd; Dr. Akshaya S. Odak, Senior Director - Regulatory, Lupin; Dr. Narendra Chirmule, Senior Vice President, Head of Research and Development, Biocon; Dr. A. K. S. Bhujanga Rao, President of R&D and Technical, Natco Pharma; Anjan Selz, Vice President - Head of Biosimilars EMEA, Lupin - Atlantis Holdings SA; Dr. Sunit Maity, Director Product Development, Zumutor Biologics any more sharing their perspective about the various biosimilar aspects of the pharma industry.
About UBM India:
UBM India is India's leading exhibition organizer that provides the industry with platforms that bring together buyers and sellers from around the world, through a portfolio of exhibitions, content led conferences and seminars. UBM India hosts over 25 large scale exhibitions and 40 conferences across the country every year; thereby enabling trade across multiple industry verticals. A UBM Asia Company, UBM India has offices across Mumbai, New Delhi, Bangalore and Chennai. UBM Asia is owned by UBM plc which is listed on the London Stock Exchange. UBM Asia is the leading exhibition organizer in Asia and the biggest commercial organizer in mainland China, India and Malaysia.
For further details, please visit http://www.ubmindia.in.
About UBM plc:
UBM plc is the largest pure-play B2B Events organiser in the world. In an increasingly digital world, the value of connecting on a meaningful, human level has never been more important. At UBM, our deep knowledge and passion for the industry sectors we serve allow us to create valuable experiences where people can succeed. At our events people build relationships, close deals and grow their businesses. Our 3,750+ people, based in more than 20 countries, serve more than 50 different sectors - from fashion to pharmaceutical ingredients. These global networks, skilled, passionate people and market-leading events provide exciting opportunities for business people to achieve their ambitions.
For more information, go to http://www.ubm.com; for UBM corporate news, follow us on Twitter at @UBM, UBM Plc LinkedIn
Media Contact: Roshni Mitra [email protected]
Mili Lalwani [email protected] ?
+91-22-61727000 UBM India
Advertisement
CPhI Conferences, a division of UBM India, which hosts a number of successful pharmaceutical conferences in the country has announced the 2nd Annual Biosimilars Congress India 2017, slated for 8th - 9th August in Hyderabad.
Advertisement
(Logo: http://mma.prnewswire.com/media/542609/UBM_CPhI_Biosimilars_Congress_India_2017_Logo.jpg )
(Logo: http://mma.prnewswire.com/media/471349/UBM_Logo.jpg )
The Indian biosimilar industry is poised for exponential growth owing to the increasing acceptance, entry of new players, and successful launch of biosimilar products. The Indian biosimilar manufacturers are striving to tap this growing opportunity through heavy investments and acquisitions. While biosimilars offer great opportunities to the Indian pharma and biopharma industry, manufacturers also face some unique R&D challenges. With the introduction of a new regulatory policy in India and increased affordability that biosimilars offer, the Indian pharmaceutical companies have started to look at biosimilars as a lucrative sector. The domestic market is expected to grow at an accelerated pace by aiming to reach a target of $40 billion by 2030 and commanding around 20% share of the global market.
CPhI's 2nd Annual Biosimilars Congress India 2017 will discuss various aspects around regulations of biosimilars, R&D, clinical research, program management and commercialisation for biosimilars. Driven by compelling content and speakers, the congress promises to be a platform for industry experts and decision makers to discuss on pertinent trends in biosimilars, deliberate on key concerns the industry faces today and offer innovative solutions that will continue to place India on the roadmap to success in biosimilars. The congress will also have practical case study insights from Indian and international experts along with panel discussions with a Q&A session.
Speaking on the upcoming 2nd Annual Biosimilars Congress India, Mr. Yogesh Mudras, Managing Director, UBM India said, "Biosimilar pathways are still evolving across the world and the major issues pharma companies face are with respect to demonstrating biosimilarity to the reference product. The changing outlook for Biosimilars comes at a time when the global pharmaceutical industry is feeling the combined impact of two key events - a period of patent expirations on many large pharma brands, and an economic situation that has required healthcare systems to make significant and sustained cost reductions. CPhI's 2nd Annual Biosimilars Congress thus comes at the right time, and aims to bring forth the challenges and opportunities to industry professionals, so that they can devise smart strategies to augment the growth of biosimilars."
The conference will also see participation from eminent speakers such as Mr. Cecil Nick, Vice President (Technical), Integrated Product Development, PAREXEL; Dr. Bhaswat S. Chakraborty, Senior Vice President, Research & Development, Cadila Pharmaceuticals Ltd; Dr. Akshaya S. Odak, Senior Director - Regulatory, Lupin; Dr. Narendra Chirmule, Senior Vice President, Head of Research and Development, Biocon; Dr. A. K. S. Bhujanga Rao, President of R&D and Technical, Natco Pharma; Anjan Selz, Vice President - Head of Biosimilars EMEA, Lupin - Atlantis Holdings SA; Dr. Sunit Maity, Director Product Development, Zumutor Biologics any more sharing their perspective about the various biosimilar aspects of the pharma industry.
About UBM India:
UBM India is India's leading exhibition organizer that provides the industry with platforms that bring together buyers and sellers from around the world, through a portfolio of exhibitions, content led conferences and seminars. UBM India hosts over 25 large scale exhibitions and 40 conferences across the country every year; thereby enabling trade across multiple industry verticals. A UBM Asia Company, UBM India has offices across Mumbai, New Delhi, Bangalore and Chennai. UBM Asia is owned by UBM plc which is listed on the London Stock Exchange. UBM Asia is the leading exhibition organizer in Asia and the biggest commercial organizer in mainland China, India and Malaysia.
For further details, please visit http://www.ubmindia.in.
About UBM plc:
UBM plc is the largest pure-play B2B Events organiser in the world. In an increasingly digital world, the value of connecting on a meaningful, human level has never been more important. At UBM, our deep knowledge and passion for the industry sectors we serve allow us to create valuable experiences where people can succeed. At our events people build relationships, close deals and grow their businesses. Our 3,750+ people, based in more than 20 countries, serve more than 50 different sectors - from fashion to pharmaceutical ingredients. These global networks, skilled, passionate people and market-leading events provide exciting opportunities for business people to achieve their ambitions.
For more information, go to http://www.ubm.com; for UBM corporate news, follow us on Twitter at @UBM, UBM Plc LinkedIn
Media Contact: Roshni Mitra [email protected]
Mili Lalwani [email protected] ?
+91-22-61727000 UBM India
